AMT-162 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administer
Phase 1/2 · Amyotrophic Lateral Sclerosis |
UniQure Biopharma B.V. | AMT-162 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|